Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort Study

Mayo Clinic Proceedings

Volumn 93, Issue 5, 2018, Pages 597-606

  Berti, Alvise ^a,b,c   Matteson, Eric L ^d,e   Crowson, Cynthia S ^d,e   Specks, Ulrich ^a   Cornec, Divi ^a,f  

^a Division of Pulmonary and Critical Care Medicine   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

^d Division of Rheumatology   (United States)

^e Department of Health Sciences Research ^*  (United States)

^f Universite de Brest   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL AORTIC ANEURYSM; ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION RESEARCH; RISK FACTOR; SMOKING; TRANSIENT ISCHEMIC ATTACK; CARDIOVASCULAR DISEASE; COMORBIDITY; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; VENOUS THROMBOEMBOLISM;

ADULT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VENOUS THROMBOEMBOLISM;

EID: 85044341953     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2018.02.010     Document Type: Article

References (45)

1. Jennette, J.C., Falk, R.J., Small-vessel vasculitis. N Engl J Med 337:21 (1997), 1512–1523.
2. Cornec, D., Cornec-Le Gall, E., Fervenza, F.C., Specks, U., ANCA-associated vasculitis— clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol 12:10 (2016), 570–579.
3. Nölle, B., Specks, U., Lüdemann, J., Rohrbach, M.S., DeRemee, R.A., Gross, W.L., Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 111:1 (1989), 28–40.
4. Fussner, L.A., Hummel, A.M., Schroeder, D.R., Silva, F., Cartin-Ceba, R., Snyder, M.R., et al., Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol 68:7 (2016), 1700–1710.
5. Finkielman, J.D., Merkel, P.A., Schroeder, D., Hoffman, G.S., Spiera, R., St Clair, E.W., et al., WGET Research Group. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Annals Intern Med 147:9 (2007), 611–619.
6. Berti, A., Cornec, D., Crowson, C.S., Specks, U., Matteson, E.L., The epidemiology of ANCA associated vasculitis in Olmsted County, Minnesota (USA): a 20 year population-based study. Arthritis Rheumatol 69:12 (2017), 2338–2350.
7. Langford, C.A., Talar-Williams, C., Barron, K.S., Sneller, M.C., Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114:6 (2003), 463–469.
8. De Groot, K., Rasmussen, N., Bacon, P.A., Tervaert, J.W., Feighery, C., Gregorini, G., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:8 (2005), 2461–2469.
9. Stone, J.H., Merkel, P.A., Spiera, R., Seo, P., Langford, C.A., Hoffman, G.S., et al., RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:3 (2010), 221–232.
10. Specks, U., Merkel, P.A., Seo, P., Spiera, R., Langford, C.A., Hoffman, G.S., et al., RAVE-ITN Research Group. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 369:5 (2013), 417–427.
11. Seo, P., Min, Y.I., Holbrook, J.T., Hoffman, G.S., Merkel, P.A., Spiera, R., et al., WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52:7 (2005), 2168–2178.
12. Avina-Zubieta, J.A., Mai, A., Amiri, N., Dehghan, N., Ann Tan, J., Sayre, E.C., et al. Risk of myocardial infarction and stroke in patients with granulomatosis with polyangiitis (Wegener's): a population-based study. Arthritis Rheumatol 68:11 (2016), 2752–2759.
13. Morgan, M.D., Turnbull, J., Selamet, U., Kaur-Hayer, M., Nightingale, P., Ferro, C.J., et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 60:11 (2009), 3493–3500.
14. Cohen Tervaert, J.W., Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 27:1 (2013), 33–44.
15. Faurschou, M., Mellemkjaer, L., Sorensen, I.J., Svalgaard Thomsen, B., Dreyer, L., Baslund, B., Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 60:4 (2009), 1187–1192.
16. Stassen, P.M., Derks, R.P., Kallenberg, C.G., Stegeman, C.A., Venous thromboembolism in ANCA-associated vasculitis–incidence and risk factors. Rheumatology (Oxford) 47:4 (2008), 530–534.
17. Weidner, S., Hafezi-Rachti, S., Rupprecht, H.D., Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 55:1 (2006), 146–149.
18. Merkel, P.A., Lo, G.H., Holbrook, J.T., Tibbs, A.K., Allen, N.B., Davis, J.C. Jr., et al., Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142:8 (2005), 620–626.
19. Novikov, P., Makarov, E., Moiseev, S., Meshkov, A., Strizhakov, L., Venous thromboembolic events in systemic vasculitis. Ann Rheum Dis, 74(3), 2015, e27.
20. Allenbach, Y., Seror, R., Pagnoux, C., Teixeira, L., Guilpain, P., Guillevin, L., French Vasculitis Study Group. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 68:4 (2009), 564–567.
21. Hilhorst, M., Winckers, K., Wilde, B., van Oerle, R., ten Cate, H., Tervaert, J.W., Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol 40:12 (2013), 2042–2046.
22. Hazebroek, M.R., Kemna, M.J., Schalla, S., Sanders-van Wijk, S., Gerretsen, S.C., Dennert, R., et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int J Cardiol 199 (2015), 170–179.
23. St. Sauver, J.L., Grossardt, B.R., Yawn, B.P., Melton, L.J. III, Rocca, W.A., Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J Epidemiol 173:9 (2011), 1059–1068.
24. St Sauver, J.L., Grossardt, B.R., Leibson, C.L., Yawn, B.P., Melton, L.J. III, Rocca, W.A., Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc 87:2 (2012), 151–160.
25. Rocca, W.A., Yawn, B.P., St Sauver, J.L., Grossardt, B.R., Melton, L.J. III, History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc 87:12 (2012), 1202–1213.
26. Leavitt, R.Y., Fauci, A.S., Bloch, D.A., Michel, B.A., Hunder, G.G., Arend, W.P., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33:8 (1990), 1101–1107.
27. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 23:4 (2002), 450–468.
28. Masi, A.T., Hunder, G.G., Lie, J.T., Michel, B.A., Bloch, D.A., Arend, W.P., et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:8 (1990), 1094–1100.
29. Jennette, J.C., Falk, R.J., Bacon, P.A., Basu, N., Cid, M.C., Ferrario, F., et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1 (2013), 1–11.
30. Watts, R., Lane, S., Hanslik, T., Hauser, T., Hellmich, B., Koldingsnes, W., et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:2 (2007), 222–227.
31. Stone, J.H., Hoffman, G.S., Merkel, P.A., Min, Y.I., Uhlfelder, M.L., Hellmann, D.B., et al., International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44:4 (2001), 912–920.
32. Ho, K.K., Anderson, K.M., Kannel, W.B., Grossman, W., Levy, D., Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88:1 (1993), 107–115.
33. Muir, R.L., Peripheral arterial disease: pathophysiology, risk factors, diagnosis, treatment, and prevention. J Vasc Nurs 27:2 (2009), 26–30.
34. Moxon, J.V., Parr, A., Emeto, T.I., Walker, P., Norman, P.E., Golledge, J., Diagnosis and monitoring of abdominal aortic aneurysm: current status and future prospects. Curr Probl Cardiol 35:10 (2010), 512–548.
35. D'Agostino, R.B. Sr., Vasan, R.S., Pencina, M.J., Wolf, P.A., Cobain, M., Massaro, J.M., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:6 (2008), 743–753.
36. Gooley, T.A., Leisenring, W., Crowley, J., Storer, B.E., Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:6 (1999), 695–706.
37. Houben, E., Penne, E.L., Voskuyl, A.E., van der Heijden, J.W., Otten, R.H.J., et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology (Oxford) 57:3 (2018), 555–562.
38. Suppiah, R., Judge, A., Batra, R., Flossmann, O., Harper, L., Höglund, P., et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 63:4 (2011), 588–596.
39. Pagnoux, C., Carette, S., Khalidi, N.A., Walsh, M., Hiemstra, T.F., Cuthbertson, D., et al., French Vasculitis Study Group (FVSG), European Vasculitis Society (EUVAS) and Vasculitis Clinical Research Consortium (VCRC). Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol, 33(2, Suppl 89), 2015 S-77-S-83.
40. Nishino, H., Rubino, F.A., DeRemee, R.A., Swanson, J.W., Parisi, J.E., Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 33:1 (1993), 4–9.
41. Sebastian, J.K., Voetsch, B., Stone, J.H., Romay-Penabad, Z., Lo, G.H., Allen, N.B., et al., Wegener's Granulomatosis Etanercept Trial Research Group. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 34:12 (2007), 2446–2450.
42. Pagnoux, C., Chironi, G., Simon, A., Guillevin, L., Atherosclerosis in ANCA-associated vasculitides. Ann NY Acad Sci 1107 (2007), 11–21.
43. Booth, A.D., Wallace, S., McEniery, C.M., Yasmin, Brown, J., Jayne, D.R., et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 50:2 (2004), 581–588.
44. George, M.G., Tong, X., Bowman, B.A., Prevalence of cardiovascular risk factors and strokes in younger adults. JAMA Neurol 74:6 (2017), 695–703.
45. Rossouw, J.E., Lewis, B., Rifkind, B.M., The value of lowering cholesterol after myocardial infarction. N Engl J Med 323:16 (1990), 1112–1119.